<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006695</url>
  </required_header>
  <id_info>
    <org_study_id>051-00</org_study_id>
    <secondary_id>UNMC-051-00</secondary_id>
    <secondary_id>COULTER-IND-3323</secondary_id>
    <nct_id>NCT00006695</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma</brief_title>
  <official_title>BEAM Plus Iodine-131 Anti-B1 Antibody and Autologous Hematopoietic Stem Cell Transplantation for Treatment of Recurrent Diffuse Large B-Cell Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver&#xD;
      cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy&#xD;
      use different ways to stop cancer cells from dividing so they stop growing or die. Combining&#xD;
      chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses&#xD;
      of chemotherapy drugs and kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well monoclonal antibody therapy, chemotherapy,&#xD;
      and peripheral stem cell transplant work in treating patients with relapsed or refractory&#xD;
      non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the response rates and time to treatment failure in patients with relapsed or&#xD;
           refractory non-Hodgkin's lymphoma treated with iodine I 131 monoclonal antibody anti-B1,&#xD;
           followed by high-dose carmustine, etoposide, cytarabine, and melphalan (BEAM), and&#xD;
           autologous peripheral blood stem cell transplantation (APBSCT) vs historical control&#xD;
           patients treated with high-dose BEAM or carmustine, etoposide, cytarabine, and&#xD;
           cyclophosphamide and APBSCT.&#xD;
&#xD;
        -  Determine the safety of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: Autologous peripheral blood stem cells (PBSC) are harvested and selected for CD34+&#xD;
      cells or granulocyte macrophage colony-forming units. On day -19, patients receive unlabeled&#xD;
      monoclonal antibody anti-B1 (MOAB anti-B1) IV followed by a dosimetric dose of iodine I 131&#xD;
      MOAB anti-B1 IV over 20 minutes. On day -12, patients receive unlabeled MOAB anti-B1 IV&#xD;
      followed by a therapeutic dose of iodine I 131 MOAB anti-B1 IV over 20 minutes. Patients then&#xD;
      receive high-dose chemotherapy comprising carmustine IV on day -6, etoposide IV and&#xD;
      cytarabine IV twice daily on days -5 to -2, and melphalan IV on day -1. Patients undergo&#xD;
      autologous PBSC transplantation on day 0.&#xD;
&#xD;
      Patients are followed at days 30 and 100, at 6 months, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study over 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2000</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">September 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>event free survival rate</measure>
    <time_frame>100 days post transpat and at yearly intervals</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to treatment failure</measure>
    <time_frame>time of registration to time of treatment discotinuation or withdrawal for progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>over all survival</measure>
    <time_frame>when all treated patients have expired</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iodine-131 Anti-B1 Antibody/BEAM/autologous hematopoietic stem cell transplantation (AHSCT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carmustine</intervention_name>
    <description>300 mg/m2 IV on Day -6</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>BCNU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>100 mg/m2 BID on Days -5 through -2</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>100 mg/m2 BID on Days -5 through -2</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>140 mg/m2 IV on Day -1</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>Following the chemotherapy, on Day 0 of treatment, the previously stored hematopoietic stem cells will be administered to the patient intravenously through a central line to the patient.</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Autologous Hematopoietic Stem Cell Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>tositumomab and iodine I 131 tositumomab</intervention_name>
    <description>Patients will receive two administrations of Iodine-131 Anti-B1 Antibody; the &quot;dosimetric dose&quot; and the &quot;therapeutic dose&quot;. The dosimetric dose will consist of an infusion of unlabeled Anti-B1 Antibody (450 mg) immediately followed by an infusion of Anti-B1 Antibody (35 mg) which has been trace labeled with 5 mCi of Iodine-131 Anti-B1 Antibody. Using whole body anterior and posterior gamma camera scans and serial imaging studies over approximately one week, the clearance of the whole body dosimetric dose will be used to calculate the subsequent therapeutic dose of Iodine-131 Anti-B1 Antibody which delivers a total body dose of 75 cGy to the subject</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Iodine-131 Anti-B1 Antibody</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of non-Hodgkin's lymphoma (NHL) of one of the following types:&#xD;
&#xD;
               -  Diffuse large B-cell&#xD;
&#xD;
               -  Composite (at least 50% of tumor showing diffuse histology)&#xD;
&#xD;
               -  Diffuse mixed cell&#xD;
&#xD;
               -  Immunoblastic&#xD;
&#xD;
          -  Relapsed or refractory disease sensitive to initial or subsequent conventional therapy&#xD;
             (at least a partial response)&#xD;
&#xD;
          -  Eligible for high-dose carmustine, etoposide, cytarabine, and melphalan protocol and&#xD;
             autologous bone marrow transplantation or peripheral blood stem cell transplantation&#xD;
&#xD;
          -  Evidence of CD20 antigen expression in tumor tissue&#xD;
&#xD;
          -  Bidimensionally measurable disease&#xD;
&#xD;
          -  No progressive disease in a field that has been previously irradiated with more than&#xD;
             3,500 cGy within the past year&#xD;
&#xD;
          -  Adequate peripheral blood stem cells&#xD;
&#xD;
               -  At least 15,000,000 CD34+ cells/kg OR&#xD;
&#xD;
               -  At least 25,000 granulocyte macrophage colony-forming units/kg&#xD;
&#xD;
          -  No known brain or leptomeningeal metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  19 to 70&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 4 months posttransplantation&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 2.0 mg/dL&#xD;
&#xD;
          -  No active obstructive hydronephrosis&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  Cardiac ejection fraction at least 40% for any of the following criteria:&#xD;
&#xD;
               -  Age 60 and over&#xD;
&#xD;
               -  Significant cardiac history (myocardial infarction or congestive heart failure)&#xD;
&#xD;
               -  Received greater than 350 mg/m^2 of prior doxorubicin&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  DLCO at least 50% of predicted&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No evidence of severe organ dysfunction&#xD;
&#xD;
          -  No other major medical illnesses&#xD;
&#xD;
          -  No active infection requiring IV antibiotics&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 6 months&#xD;
             after study participation&#xD;
&#xD;
          -  Human antimouse antibody negative&#xD;
&#xD;
          -  No vulnerability&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior peripheral blood stem cell transplantation following high-dose chemotherapy&#xD;
             or chemoradiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior biologic therapy and recovered&#xD;
&#xD;
          -  No other concurrent biologic therapy for NHL&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Biologic therapy&#xD;
&#xD;
          -  At least 4 weeks since prior cytotoxic chemotherapy and recovered&#xD;
&#xD;
          -  No other concurrent chemotherapy or antineoplastic therapy for NHL&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent steroids except maintenance-dose steroids for noncancerous disease&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Biologic therapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent external beam radiotherapy for NHL&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 4 weeks since prior immunosuppressants and recovered&#xD;
&#xD;
          -  No other concurrent participation on protocol involving non-FDA-approved drugs or&#xD;
             biologics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie M. Vose, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNMC Eppley Cancer Center at the University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-6805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>December 6, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 26, 2015</last_update_submitted>
  <last_update_submitted_qc>May 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Julie M Vose, MD</investigator_full_name>
    <investigator_title>Professor &amp; N/M Harris Oncology Professorship</investigator_title>
  </responsible_party>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Tositumomab I-131</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

